Back to top
more

Aduro Biotech, Inc. (ADRO)

(Delayed Data from NSDQ)

$4.26 USD

4.26
328,546

+0.11 (2.65%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Prothena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment

by Zacks Equity Research

Prothena Corporation plc (PRTA) reported a narrower-than-expected loss in the second quarter as the company received a milestone payment from Roche.

    Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss

    by Zacks Equity Research

    Endocyte (ECYT) second quarter loss was wider than expected. The company has announced restructuring initiatives to shift its pipeline focus to CAR-T cell platform.

      Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View

      by Zacks Equity Research

      Zoetis (ZTS) reported impressive second-quarter results beating on both counts. The new launches and expansion of market for major products helped revenue growth.

        Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered

        by Zacks Equity Research

        Endo (ENDP) beat second-quarter 2017 earnings and sales. However, revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.

          Mallinckrodt (MNK) Tops Q2 Earnings, Generics Segment Weak

          by Zacks Equity Research

          Mallinckrodt Public Limited Company (MNK) reported second-quarter 2017 results wherein earnings beat expectations but sales missed the same.

            Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected

            by Zacks Equity Research

            Arena Pharmaceuticals (ARNA) reported another quarter of lackluster Belviq sales. However, the company is expected to advance ralinpeg in phase III study soon based on positive phase II study results.

              VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y

              by Zacks Equity Research

              VIVUS reported dismal second-quarter results wherein its loss widened from the year-ago period on lower sales.

                Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top

                by Zacks Equity Research

                Aduro (ADRO) incurs loss in Q2 but revenues beat estimates. However, the same declines year over year, courtesy a milestone payment from the year-ago quarter.

                  AstraZeneca (AZN) Beats on Q2 Earnings, Falls on Failed Study

                  by Zacks Equity Research

                  AstraZeneca PLC (AZN) reported second-quarter 2017 core earnings of 87 cents per ADS, which beat the Zacks Consensus Estimate of 41 cents. Failure in lung cancer study on Imfinzi however pulled the stock down.

                    Mirati Therapeutics (MRTX) Rises: Stock Moves 11.5% Higher

                    by Zacks Equity Research

                    Mirati Therapeutics, Inc. (MRTX) shares rose over 11% in the last trading session.

                      Alexion Reportedly Being Investigated by HHS, Shares Slip

                      by Zacks Equity Research

                      Shares of Alexion Pharmaceuticals, Inc. (ALXN) were down more than 3% on Thursday after a Bloomberg report stated that it is under investigation by the U.S. Department of Health and Human Services' (HHS) Office of Inspector General (OIG).

                        Verastem (VSTM) Shows Strength: Stock Adds 42% in Session

                        by Zacks Equity Research

                        Verastem, Inc. (VSTM) shares jumped almost 42% in the last trading session.

                          Celsion Completes Ovarian Cancer Trial Enrollment, Stock Up

                          by Zacks Equity Research

                          Celsion Corp. (CLSN) shares rose after the company has announced completion of enrolment in a phase Ib study, evaluating its immunotherapy, GEN-1 in combination with neoadjuvant chemotherapy for treatment of advanced ovarian cancer.

                            Geron Stock Up Almost 40% So Far This Year After '16 Decline

                            by Zacks Equity Research

                            Geron Corporation's (GERN) shares have risen 38.7% this year so far, outperforming the Zacks classified Medical - Biomedical and Genetics industry, which rose 5.6%. This comes after a decline of more than 57% in 2016.

                              Aduro Starts Phase II Combo Study with CRS-207 & Keytruda

                              by Zacks Equity Research

                              Aduro Biotech, Inc. (ADRO) has announced initiation of a phase II study to evaluate a combination therapy of its lead candidate, CRS-207, in combination with Keytruda, for treatment of patients with pleural mesothelioma (MPM).

                                Can Aduro BioTech (ADRO) Run Higher on Strong Earnings Estimate Revisions?

                                by Zacks Equity Research

                                Aduro BioTech, Inc. (ADRO) is an immunotherapy company that could be an interesting play for investors.

                                  Aduro's Drug Gets Clearance by the FDA for Solid Tumors

                                  by Zacks Equity Research

                                  Aduro Biotech, Inc. (ADRO) announced that the FDA has cleared the Investigational New Drug application (IND) for its pipeline candidate ADU-S100 (MIW815).

                                    Why Is Aduro (ADRO) Down 3.6% Since the Last Earnings Report?

                                    by Zacks Equity Research

                                    Aduro (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                      Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4

                                      by Zacks Equity Research

                                      Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.

                                        Aduro (ADRO) Inks License Agreement with Stanford University

                                        by Zacks Equity Research

                                        Aduro Biotech, Inc. (ADRO) announced that it has inked an exclusive license agreement with Stanford University for state-of-the-art neo-antigen identification technology.